Amsterdam, March 1, 2022 — LSP, the European life sciences and healthcare investment firm, today announced that the closing of it’s acquisition by EQT took place on February 28, 2022. Henceforth, LSP will be called EQT Life Sciences.
On November 10, 2021, LSP announced that it will join forces with EQT AB (“EQT”), one of the largest private equity firms in Europe and among the top-ten private equity firms globally. The press release can be found here (link). EQT's acquisition of LSP is driven by the complementarity of investment expertise between the firms as well as significant growth opportunities and scale benefits. As part of EQT, LSP will be able to continue its strategy and operations as it has done successfully over the past years while leveraging the added value of being part of the EQT family.
René Kuijten, Managing Partner at LSP, and incoming Partner and Head of EQT Life Sciences, said, “Europe has many attractive life sciences companies. Together with EQT, one of the largest European private equity firms with more than EUR 73 billion in assets under management, LSP can select, develop, and finance these opportunities even better than before. Given the strong cultural fit and the complementarity between our organisations, we are convinced that joining forces is a win-win for our investors, our portfolio companies, our LSP colleagues, and the broader European life sciences ecosystem.”
For more information, please contact:
René R. Kuijten, MD PhD MBA
Partner, Head of EQT Life Sciences
About EQT Life Sciences
EQT Life Sciences was formed in 2022 following the integration of LSP, a leading European life sciences and healthcare investment firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor.
More info: www.eqtgroup.com/lifesciences
EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of almost three decades of delivering consistent and attractive returns across multiple geographies, sectors and strategies. Uniquely, EQT is the only large private markets firm in the world with investment strategies covering all phases of a business’ development, from start-up to maturity. EQT today has EUR 73.4 billion in assets under management across 28 active funds within two business segments – Private Capital and Real Assets.
With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does.
The EQT AB Group comprises EQT AB (publ) and its direct and indirect subsidiaries, which include general partners and fund managers of EQT funds as well as entities advising EQT funds. EQT has offices in 24 countries across Europe, Asia-Pacific and the Americas and approximately 1,200 employees.
More info: www.eqtgroup.com